These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 8228239)
1. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239 [TBL] [Abstract][Full Text] [Related]
2. Analysis of T-cell receptor V region gene usage of cytotoxic T-lymphocytes and tumor-infiltrating lymphocytes derived from human autologous gastric signet ring cell carcinomas. Ikeda H; Sato N; Matsuura A; Kikuchi K Cancer Res; 1993 Jul; 53(13):3078-84. PubMed ID: 8391386 [TBL] [Abstract][Full Text] [Related]
3. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829 [TBL] [Abstract][Full Text] [Related]
4. The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Weidmann E; Whiteside TL; Giorda R; Herberman RB; Trucco M Cancer Res; 1992 Nov; 52(21):5913-20. PubMed ID: 1382847 [TBL] [Abstract][Full Text] [Related]
7. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652 [TBL] [Abstract][Full Text] [Related]
8. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors. Heo DS; Whiteside TL; Kanbour A; Herberman RB J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766 [TBL] [Abstract][Full Text] [Related]
9. Selective usage of TCR V beta in tumor-specific CTL lines isolated from ovarian tumor-associated lymphocytes. Ioannides CG; Freedman RS Anticancer Res; 1991; 11(5):1919-25. PubMed ID: 1722660 [TBL] [Abstract][Full Text] [Related]
10. Analysis of T cell receptor alpha beta variability in tumor-infiltrating lymphocytes in primary and metastatic melanoma. Zeuthen J; Birck A; Straten PT Arch Immunol Ther Exp (Warsz); 1995; 43(2):123-33. PubMed ID: 8744727 [TBL] [Abstract][Full Text] [Related]
11. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. Choudhary A; Davodeau F; Moreau A; Peyrat MA; Bonneville M; Jotereau F J Immunol; 1995 Apr; 154(8):3932-40. PubMed ID: 7706731 [TBL] [Abstract][Full Text] [Related]
13. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Gervois N; Heuze F; Diez E; Jotereau F Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794 [TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Dadmarz RD; Ordoubadi A; Mixon A; Thompson CO; Barracchini KC; Hijazi YM; Steller MA; Rosenberg SA; Schwartzentruber DJ Cancer J Sci Am; 1996; 2(5):263-72. PubMed ID: 9166543 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. Ioannides CG; Freedman RS; Platsoucas CD; Rashed S; Kim YP J Immunol; 1991 Mar; 146(5):1700-7. PubMed ID: 1704404 [TBL] [Abstract][Full Text] [Related]
16. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]